- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01983670
The Investigation of the Pre-movement Facilitation of Agonist-antagonist Muscles and the Effect of the Feedforward Rehabilitation in Individuals With Hypermetria
In individuals with spino-cerebellar atrophy (SCA), the delayed onset of antagonist muscle firing has been reported to be the cause of hypermetria. Hypermetria is a common deficit in individuals with spino-cerebellar atrophy SCA when they perform ballistic goal-directed movement. Based on the previous studies, ballistic goal-directed movements are controlled by a triphasic pattern of agonistic and antagonistic muscle activation. The origin of the EMG pattern is a central program, whereas the delayed onset of antagonistic muscle firing has been reported to be the cause of hypermetria. To develop a therapy method, the difference in temporal pattern and intensity of supraspinal excitability of agonist and antagonist bursts between healthy adults and individuals with SCA when performing rapid and slow goal-directed movements should be further investigated.
Traditional rehabilitations of individuals with cerebellum lesion were limited to improve the functional performance of movement. Since the deficits of the goal-directed movement are at pre-movement programming, only feedforward training will be possible to re-establish an appropriate program.
Previous showed that peripheral stimulation resulted in a facilitation of motor cortex. Our group also found that this facilitation in individuals with SCA was similar to the ones without SCA. Therefore, it is possible to adjust the control pattern of supraspinal excitability of agonist and antagonist busts of SCA patient with passively providing electrical stimulation contains normal control pattern of healthy human.
The present study sought to investigate the difference in temporal pattern and intensity of supraspinal excitability of agonist and antagonist bursts between healthy adults and individuals with SCA when performing rapid and slow goal-directed movements.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Taoyuan, Taiwan, 333
- Chang Gung University
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Clinical diagnosis of spinocerebellar ataxia
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: health group 1
Health subjects received 30 mins delay antagonist activation temporal ES.
|
|
Eksperimentel: SCA group 1
SCA subjects received four weeks temporal ES assisted home training program.
|
|
Ingen indgriben: health group 2
health subjects controlled group
|
|
Ingen indgriben: SCA group 2
SCA subjects controlled group
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Muscle evoked potential(MEP)
Tidsramme: Baseline, 4 weeks.
|
Measure of changes in MEP of flexor carpi radialis.
|
Baseline, 4 weeks.
|
Electromyography(EMG)
Tidsramme: Baseline, 4 weeks
|
Measure of changes in EMG of flexor carpi radialis and extensor carpi radialis.
|
Baseline, 4 weeks
|
Movement error
Tidsramme: Baseline, 4weeks
|
Measure of changes in movement error during fast 30 degrees wrist extensions.
|
Baseline, 4weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Neurologiske manifestationer
- Genetiske sygdomme, medfødte
- Neurodegenerative sygdomme
- Dyskinesier
- Rygmarvssygdomme
- Heredodegenerative lidelser, nervesystem
- Cerebellære sygdomme
- Ataksi
- Cerebellar ataksi
- Spinocerebellære ataksier
- Spinocerebellare degenerationer
Andre undersøgelses-id-numre
- 98-0951B
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Spinocerebellar Atrophy (SCA)
-
Biohaven Pharmaceuticals, Inc.LedigSpinocerebellære ataksier | SCA
-
Chang Gung UniversityRekruttering
-
Laura Alice Santos OliveiraFederal Institute of Rio de JaneiroTilmelding efter invitationGangataksi | Postural balance | SCABrasilien
-
Cadent TherapeuticsTrukket tilbageSpinocerebellar ataksi type 3 | Spinocerebellære ataksier | Spinocerebellar ataksi type 1 | Spinocerebellar ataksi type 2 | Spinocerebellar ataksi type 6 | Spinocerebellar ataksi type 10 | Spinocerebellar ataksi type 7 | Spinocerebellar ataksi type 8 | Spinocerebellar ataksi type 17 | ARCA1 - Autosomal recessiv...Forenede Stater
-
Biohaven Pharmaceuticals, Inc.Aktiv, ikke rekrutterendeSpinocerebellære ataksier | Spinocerebellar Ataksi Genotype Type 1 | Spinocerebellar Ataksi Genotype Type 2 | Spinocerebellar Ataksi Genotype Type 3 | Spinocerebellar Ataxia Genotype Type 6 | Spinocerebellar Ataksi Genotype Type 7 | Spinocerebellar Ataxia Genotype Type 8 | Spinocerebellar Ataxia Genotype...Forenede Stater
-
Biohaven Pharmaceuticals, Inc.Aktiv, ikke rekrutterendeSpinocerebellar ataksi type 3 | Spinocerebellære ataksier | Spinocerebellar ataksi type 1 | Spinocerebellar ataksi type 2 | Spinocerebellar ataksi type 6 | Spinocerebellar ataksi type 10 | Spinocerebellar ataksi type 7 | Spinocerebellar ataksi type 8Forenede Stater, Kina
-
Teachers College, Columbia UniversityAktiv, ikke rekrutterendeSpinocerebellar ataksi type 3 | Spinocerebellar ataksi type 1 | Spinocerebellar ataksi type 2 | Spinocerebellar ataksi type 6 | Spinocerebellar ataksi type 7Forenede Stater
-
University of FloridaUniversity of California, Los Angeles; National Ataxia FoundationRekrutteringSpinocerebellar ataksi type 3 | Spinocerebellar ataksi type 1 | Spinocerebellar ataksi type 2 | Spinocerebellar ataksi type 6Forenede Stater
-
University of FloridaAcorda TherapeuticsAfsluttetSpinocerebellar ataksi type 1 | Spinocerebellar ataksi type 2 | Spinocerebellar ataksi type 3 | Spinocerebellar ataksi type 6Forenede Stater
-
Sclnow Biotechnology Co., Ltd.Ikke rekrutterer endnuSpinocerebellar ataksi type 3 | Spinocerebellar ataksi type 1 | Spinocerebellar ataksi type 2 | Spinocerebellar ataksi type 6
Kliniske forsøg med Temporal electrical stimulation
-
University Hospital MuensterUkendtSlag | Dysfagi | EkstubationsfejlTyskland
-
Phagenesis Ltd.NAMSA; Cytel Inc.RekrutteringDysfagiFinland, Schweiz, Østrig, Tyskland
-
University of Sao Paulo General HospitalAktiv, ikke rekrutterendeTraumatisk hjerneskade | Post-hjernerystelse SymptomerBrasilien
-
Nu Eyne Co., Ltd.AfsluttetTør øjensygdomKorea, Republikken
-
US Department of Veterans AffairsAfsluttetKardiovaskulær sygdom | RygmarvsskadeForenede Stater
-
Medtronic Corporate Technologies and New VenturesAfsluttet
-
Medical College of WisconsinChildren's Wisconsin; Advancing a Healthier Wisconsin Endowment (AHW)RekrutteringParoksysmal sympatisk hyperaktivitetForenede Stater
-
University of MiamiFloridaAfsluttetNeuropatisk smerteForenede Stater
-
Spaulding Rehabilitation HospitalAfsluttetRygmarvsskadeForenede Stater
-
Universidade Federal de Santa MariaAfsluttet